Alzheimer's disease and coffee: A quantitative review

Neurological Research

Volumn 29, Issue 1, 2007, Pages 91-95

  Barranco Quintana, José Luis ^a   Allam, Mohamed Farouk ^a   Del Castillo, Amparo Serrano ^a   Navajas, Rafael Fernández Crehuet ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Alzheimer's disease; Coffee; Meta analysis; Quantitative review; Systematic review

Indexed keywords

ALZHEIMER DISEASE; COFFEE; CONFIDENCE INTERVAL; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HUMAN; NEUROPROTECTION; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; CASE-CONTROL STUDIES; COFFEE; COHORT STUDIES; FOOD HABITS; HUMANS; QUESTIONNAIRES; RISK FACTORS;

EID: 33846634161     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313206X152546     Document Type: Review

References (32)

1. Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: Results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999; 52: 78-84
2. Ott A, Breteler MMB, van Harskamp F, et al. Incidence and risk of dementia: The Rotterdam study. Am J Epidemiol 1998; 147: 574-580
3. Fratiglioni L. Epidemiology of Alzheimer's disease and current possibilities for prevention. Acta Neurol Scand 1996; 165: S33-S40
4. Alloul K, Sauriol L, Kennedy W, et al. Alzheimer's disease: A review of the disease, its epidemiology and economic impact. Arch Gerontol Geriatrics 1998; 27: 189-221
5. Shalat SL, Seltzer B, Pidcock C, et al. Risk factors for Alzheimer's disease: A case-control study. Neurology 1987; 37: 1630-1633
6. Fourrier A, Letenneur L, Begaud B, et al. Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: Inconclusive results from a population-based cohort study. J Clin Epidemiol 1996; 49: 1201
7. de Mendonca A, Sebastiao AM, Ribeiro JA. Adenosine: Does it have a neuroprotective role after all? Brain Res Rev 2000; 33: 258-274
8. Fredholm BB, Battig K, Holmen J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133
9. Tyas SL, Manfreda J, Strain LA, et al. Risk factors for Alzheimer's disease: A population based, longitudinal study in Manitoba, Canada. Int J Epidemiol 2001; 30: 590-597
10. Maia L, de Mendonca A. Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 2002; 9: 377-382
11. 2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 2003; 138: 1207-1209
12. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002; 156: 445-453
13. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990; 40: 1698-1707
14. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 121-145
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
16. Greenberg SM, Bacskai BJ, Hyman Bt. Alzheimer disease's double-edged vaccine. Nat Med 2003; 9: 389-390
17. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342
18. Sleegers K, Van Duijin CM. Alzheimer's disease: Genes, pathogenesis and risk prediction. Community Genet 2001; 4: 197-203
19. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30
20. Martin EM, Wilson RS, Penn RD, et al. Cortical biopsy results in Alzheimer's disease: Correlation with cognitive deficits. Neurology 1987; 37: 1201-1204
21. Morris JC, McKeel DW, Jr, Fulling K, et al. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol 1988; 24: 17-22
22. Shadlen MF, Larson EB. What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. Postgrad Med 1999; 105: 109-118
23. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study Group. Arch Neurol 2004; 61: 82-88
24. Engelhart MJ, Geerlings MI, Ruitenberg A. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287: 3223-3229
25. Morris MC, Evans DA, Bienias JL. Dietary intake of antioxidant nutrients ant the risk of incident Alzheimer's disease in biracial community study. JAMA 2002; 287: 3230-3237
26. Sano M. Do dietary antioxidants prevent Alzheimer's disease? Lancet Neurol 2002; 1: 342
27. Azam S, Hadi N, Khan NU, et al. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med Sci Monit 2003; 9: BR325-BR330
28. Kleemola P, Jousilahti P, Pietinen P, et al. Coffee consumption and the risk of coronary heart disease and death. Arch Intern Med 2000; 160: 3393-3400
29. Graves AB, Van Duijin CM, Chandra V, et al. Alcohol and tobacco consumption as risk factor for Alzheimer's disease: A collaborative re-analysis of case-control studies. Int J Epidemiol 1991; 20 (Suppl. 2): S48-S57
30. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: Review of the epidemiological studies. Behav Brain Res 2000; 113: 117-120
31. Orgogozo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997; 153: 185-192
32. Willems-Giesbergen PCLM, de Rijk MC, van Switen JC, et al. Smoking, alcohol, and coffee consumption and the risk of PD: Results from the Rotterdam Study. Neurology 2001; 54: A347-A348